title: MPA: a treatment option for lymphocytic colitis and mesalamine-induced interstitial nephritis.
authors.forename: J
authors.initials: J
authors.lastname: Halbritter
authors.forename: H
authors.initials: H
authors.lastname: Wittenburg
authors.forename: I
authors.initials: I
authors.lastname: Schiefke
authors.forename: K
authors.initials: K
authors.lastname: Amann
authors.forename: T
authors.initials: T
authors.lastname: Lindner
authors.forename: F M
authors.initials: FM
authors.lastname: Rasche
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects; D046730:Colitis, Lymphocytic / Q000150:complications / Q000188:drug therapy*; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D019804:Mesalamine / Q000009:adverse effects; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000627:therapeutic use*; D009395:Nephritis, Interstitial / Q000139:chemically induced / Q000150:complications / Q000188:drug therapy*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D004791:Enzyme Inhibitors; D019804:Mesalamine; D009173:Mycophenolic Acid